Abstract
Fibroblast growth factors (FGF) have pleiotropic roles in human development and metabolism, and FGF signaling through FGF receptors (FGFRs) has been implicated in a wide range of cancers. Extensive pre-clinical and clinical studies are currently underway to elucidate the therapeutic possibilities: monoclonal antibodies, ligand traps, heparanoids, and kinase inhibitors all have potential for the treatment of FGFR-driven cancers.
Author supplied keywords
- A-loop tyrosine phosphorylation
- Aberrant FGF
- Brivanib
- CRKL
- Core homology region
- Dovitinib
- ELISA
- Endocrine FGFs
- Exon 8 and exon 9
- FGF receptor (FGFR)
- FGFR binding specificity
- FGFR dimerization
- FGFR1-3 genes
- FRS2α, 3
- Fibroblast growth factor (FGF)
- Immunohistochemical staining
- Mechanisms
- Overexpression
- Palifermin
- Paracrine-acting FGF subfamilies
- Preclinical studies
- Prognostic markers
- Pyruvate kinase
- Role in cancer
- Signaling
- Single nucleotide polymorphisms (SNPs)
- Somatic mutations
- Subfamilies
- Therapy
Cite
CITATION STYLE
APA
Mohammadi, M., & Beenken, A. (2017). FGF-FGFR signaling in cancer. In Cancer Therapeutic Targets (Vol. 2–2, pp. 577–590). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_19
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free